Alopecia Pipeline Insight
DelveInsight’s, “Alopecia - Pipeline Insight, 2023,” report provides comprehensive insights about 33+ companies and 33+ pipeline drugs in Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
- Global coverage
Alopecia is the loss of hair in areas anywhere on the body where hair normally grows. Alopecia may be defined as scarring or non-scarring, localized or diffuse, congenital or acquired, reversible or permanent, or confined to the scalp or universal; however, alopecia is usually classified using the 1st 3 factors. The etiologies of alopecia are usually divided into disorders in which the hair follicle is abnormal or damaged and those in which the hair follicle is normal but the cycling of hair growth is abnormal. The most common presentations are androgenetic hair loss, alopecia areata, traction alopecia, tinea capitis, and telogen effluvium. Diagnosis is made through a positive medical history and physical exam findings. Treatment depends on the type and potential for regrowth.
"Alopecia - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alopecia pipeline landscape is provided which includes the disease overview and Alopecia treatment guidelines. The assessment part of the report embraces, in depth Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Alopecia.
- In the coming years, the Alopecia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Alopecia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Alopecia treatment market. Several potential therapies for Alopecia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Alopecia market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Alopecia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Alopecia Emerging Drugs Chapters
This segment of the Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alopecia Emerging Drugs
KX-826: Kintor Pharma
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (AGA) and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile. On 11 July 2021, Kintor Pharma announced that the Food and Drug Administration of the United States greenlighted KX-826’s phase II clinical trial for AGA to be conducted in the United States. On 31 December 2021, Kintor Pharma announced the first patient dosing in its phase III clinical trial of KX-826 in China for the treatment of male AGA patients, with 26 sites participating in this trial. On 12 November 2021, Kintor Pharma announced the first patient dosing in its phase II clinical trial of KX-826 in China for the treatment of female AGA patients. For the acne vulgaris indication, on 24 January 2022, Kintor Pharma announced the first patient dosing in its phase II clinical trial of KX-826 in China for the treatment of acne vulgaris.
Baricitinib: Reata Pharmaceuticals
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators.
Further product details are provided in the report……..
Alopecia: Therapeutic Assessment
This segment of the report provides insights about the different Alopecia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Alopecia
There are approx. 33+ key companies which are developing the therapies for Alopecia. The companies which have their Alopecia drug candidates in the most advanced stage, i.e. phase III include Kintor Pharma.
DelveInsight’s report covers around 33+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous/ Subcutaneous
Products have been categorized under various Molecule types such as
- Antisense oligonucleotides
- Monoclonal antibody
- Recombinant protein
- Small molecule
- Stem Cell
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Alopecia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alopecia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alopecia drugs.
Alopecia Report Insights
- Alopecia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Alopecia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alopecia drugs?
- How many Alopecia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alopecia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alopecia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alopecia and their status?
- What are the key designations that have been granted to the emerging drugs?